http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Hee Ryeong Jang,Moo-Kon Song,정주섭,양덕환,Jeong Ok Lee,Junshik Hong,조수희,Seong Jang Kim,신동훈,Young Joo Park,강진숙,Jeong Eun Lee,이문원,신호진 대한혈액학회 2015 Blood Research Vol.50 No.2
BackgroundFew clinical studies have clarified the prognostic factors that affect clinical outcomes forpatients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) afterimmunochemotherapy. MethodsA total of 158 patients with relapsed or refractory DLBCL were enrolled. All patients underwentpositron emission tomography/computed tomography (PET/CT) before and aftersalvage therapy. All enrolled patients previously received the ifosfamide, carboplatin, andetoposide regimen. Clinical outcomes were compared according to several factors (age ≥ 65 years, low age-adjusted International Prognostic Index [aa-IPI], maximum standardizeduptake value [SUVmax] <6.0 on PET/CT, time to relapse ≥12 months, completeresponse after salvage therapy). A low aa-IPI, SUVmax <6.0, and time to relapse ≥ 12months were independent prognostic factors for survival. ResultsIn univariate analysis and multivariate analysis, SUVmax below 6.0 (P<0.001 for progression-free survival (PFS), P<0.001 for overall survival (OS)) and low aa-IPI (P<0.001for PFS, P<0.001 for OS) were independent prognostic factors associated with favorableoutcome. ConclusionThe aa-IPI and initial SUVmax were powerful prognostic factors in patients with relapsedor refractory DLBCL.
Hee Ryeong Jang,Moo-Kon Song,정주섭,양덕환,Jeong Ok Lee,Junshik Hong,조수희,Seong Jang Kim,신동훈,Young Joo Park,강진숙,Jeong Eun Lee,이문원,신호진 대한혈액학회 2015 Blood Research Vol.50 No.2
BackgroundFew clinical studies have clarified the prognostic factors that affect clinical outcomes forpatients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) afterimmunochemotherapy. MethodsA total of 158 patients with relapsed or refractory DLBCL were enrolled. All patients underwentpositron emission tomography/computed tomography (PET/CT) before and aftersalvage therapy. All enrolled patients previously received the ifosfamide, carboplatin, andetoposide regimen. Clinical outcomes were compared according to several factors (age ≥ 65 years, low age-adjusted International Prognostic Index [aa-IPI], maximum standardizeduptake value [SUVmax] <6.0 on PET/CT, time to relapse ≥12 months, completeresponse after salvage therapy). A low aa-IPI, SUVmax <6.0, and time to relapse ≥ 12months were independent prognostic factors for survival. ResultsIn univariate analysis and multivariate analysis, SUVmax below 6.0 (P<0.001 for progression-free survival (PFS), P<0.001 for overall survival (OS)) and low aa-IPI (P<0.001for PFS, P<0.001 for OS) were independent prognostic factors associated with favorableoutcome. ConclusionThe aa-IPI and initial SUVmax were powerful prognostic factors in patients with relapsedor refractory DLBCL.